Who are Ursodeoxycholic acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bylvay, Livmarli, Cholbam, Welchol, Actigall, Chenix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ursodeoxycholic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ursodeoxycholic acid — Competitive Intelligence Brief

Ursodeoxycholic acid (Ursodeoxycholic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid. Area: Hepatology/Gastroenterology.

marketed Bile acid Farnesoid X receptor (FXR), TGR5 receptor Hepatology/Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ursodeoxycholic acid (Ursodeoxycholic acid) — University of Oxford. Ursodeoxycholic acid is a bile acid that reduces cholesterol saturation in bile and increases bile flow to improve hepatic function and reduce cholestasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ursodeoxycholic acid TARGET	Ursodeoxycholic acid	University of Oxford	marketed	Bile acid	Farnesoid X receptor (FXR), TGR5 receptor
Bylvay	ODEVIXIBAT	Ipsen	marketed	Ileal Bile Acid Transporter Inhibitor [EPC]	Ileal sodium/bile acid cotransporter	2021-01-01
Livmarli	maralixibat hydrochloride	Mirum Pharma Inc	marketed	Ileal Bile Acid Transporter Inhibitor	Ileal sodium/bile acid cotransporter	2021-01-01
Cholbam	CHOLIC ACID	Mirum	marketed	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Welchol	COLESEVELAM	Cosette	marketed	Bile Acid Sequestrant		2000-01-01
Actigall	URSODIOL	AbbVie	marketed	Bile Acid [EPC]	CDGSH iron-sulfur domain-containing protein 1	1987-01-01
Chenix	CHENODIOL		marketed	Bile Acid [EPC]	Bile acid receptor	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-05-26 — Livmarli · 11260053 · US
2032-10-26 — Livmarli · 11376251 · US
2040-02-12 — Livmarli · 11497745 · US
2040-02-12 — Livmarli · 11229647 · US

Sponsor landscape (Bile acid class)

Beijing Friendship Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
University of Oxford · 1 drug in this class
Xijing Hospital of Digestive Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ursodeoxycholic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/ursodeoxycholic-acid. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab